Enabling High-Performing Perfusion Cell Culture

It is estimated that by 2025, 35% of biologics will be manufactured using process intensification methods, including perfusion-based bioprocessing. Advancement of the biopharma industry in this direction means there will be significantly higher demands placed upon both the equipment and consumables to drive these processes forward. This increased interest in performance creates an opportunity for improvement in consistent scalability as well as process design and management.

Follow along as we examine two innovations to increase process performance and clear a path toward production scale-up.